Bowel ulceration following tocilizumab administration in a COVID-19 patient
Bowel ulceration following tocilizumab administration in a COVID-19 patient
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Tocilizumab, a monoclonal antibody against interleukin-6, has been used to treat cytokine release syndrome (CRS) in a subset of patients with severe COVID-19 disease. Acute ulcerative bowel disease has been only rarely documented in patients treated for rheumatological conditions. The gastrointestinal side effects seen when used in the context of C...
Alternative Titles
Full title
Bowel ulceration following tocilizumab administration in a COVID-19 patient
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0263cfb18a504b66b690a34c72947587
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0263cfb18a504b66b690a34c72947587
Other Identifiers
ISSN
2054-4774
E-ISSN
2054-4774
DOI
10.1136/bmjgast-2020-000484
